Posted by Michael Wonder on 14 Dec 2022
PHARMAC to fund the EpiPen for severe allergies
15 December 2022 - PHARMAC has confirmed today that it will be fully funding the EpiPen brand of adrenaline auto injectors from 1 February 2023, which will benefit thousands of New Zealanders.
“We are pleased to be able to share that adrenaline auto-injectors will be funded for anyone who has previously experienced a severe allergic reaction, known as anaphylaxis, or anyone who is at significant risk,” says PHARMAC’s director of operations Lisa Williams.
